SMS LIFESCIENCES INDIA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 760.3 INR | +2.08% |
|
-1.80% | +43.56% |
| 05-27 | SMS Lifesciences India Limited Recommends Final Dividend for the Year 2023-24 | CI |
| 05-27 | SMS Lifesciences India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 3.5B 41.91M 57.31M | Sales 2023 | 3.16B 37.81M 51.71M | Capitalization | 1.54B 18.48M 25.27M |
|---|---|---|---|---|---|
| Net income 2022 | 253M 3.03M 4.15M | Net income 2023 | 115M 1.38M 1.88M | EV / Sales 2022 | 0.82 x |
| Net Debt 2022 | 764M 9.15M 12.52M | Net Debt 2023 | 969M 11.61M 15.88M | EV / Sales 2023 | 0.8 x |
| P/E ratio 2022 |
8.35
x | P/E ratio 2023 |
13.5
x | Employees | 567 |
| Yield 2022 |
0.21% | Yield 2023 |
0.29% | Free-Float | 26.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.08% | ||
| 1 week | -1.80% | ||
| Current month | -0.16% | ||
| 1 month | +14.16% | ||
| 3 months | +27.99% | ||
| 6 months | +45.97% | ||
| Current year | +43.56% |
1 week
681.05
794.00
1 month
626.45948.00
Current year
521.60948.00
1 year
472.05948.00
3 years
472.051 024.90
5 years
152.651 024.90
10 years
128.451 024.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 16-03-31 | |
| Director of Finance/CFO | - | 17-05-31 | |
| Compliance Officer | - | 20-02-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 16-12-31 | |
| Chief Executive Officer | 64 | 16-03-31 | |
| Director/Board Member | 67 | 17-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 760.3 | +2.08% | 3,987 |
| 24-06-05 | 744.8 | +5.04% | 8,336 |
| 24-06-04 | 709 | -8.43% | 5,049 |
| 24-06-03 | 774.3 | +1.68% | 4,549 |
| 24-05-31 | 761.5 | -1.64% | 8,401 |
End-of-day quote NSE India S.E., June 05, 2024
More quotes
SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +43.56% | 27.53M | |
| +43.64% | 754B | |
| +39.42% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +11.92% | 217B | |
| -2.62% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- SMSLIFE Stock
